Search Results - non-cancer+therapeutics

70 Results

Sort By:

  1. Brain-Targeted Nanoparticles for Delivering Agents to the Brain
    The blood brain barrier (BBB) is a highly selective semipermeable complex, and only about 2% of small molecules in the blood can penetrate it. Because of this, drug delivery to the brain is fairly ineffective. Research into receptors expressed on the BBB is promising, however, many receptors (glucose transporter 1, transferrin receptor, LDL-receptor...
    Published: 8/27/2025
    Inventor(s): Shu Wang, Zhaoyang Fan
    Keywords(s):  
    Category(s): Biological Nanotechnology, Diagnostic Assays/Devices, Imaging, Life Science (All LS Techs), Pharmaceuticals, Medical Imaging, Non-Cancer Therapeutics
  2. Antibody based reagents that specifically recognize toxic oligomeric forms of beta-amyloid
    Neurodegenerative diseases such as Alzheimer’s are affecting an increasing number, with annual new diagnoses approaching one-half million; and total cost, $150 billion. Early diagnosis and treatment are important for optimal outcomes, yet there is currently no test to detect such diseases in their early, asymptomatic stages. Active immuniza-tion...
    Published: 8/27/2025
    Inventor(s): Michael Sierks, Srinath Kasturirangan
    Keywords(s): Bio-Technology, Therapeutics
    Category(s): Life Science (All LS Techs), Diagnostic Assays/Devices, Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools, Medical Diagnostics/Sensors
  3. Compounds to Modulate Retinoid X Receptors
    The human retinoid X receptors (RXRs) function as transcriptional regulators, often in partnership with members of a larger nuclear receptor family of transcription factors. RXR agonists have been shown to modulate RXR transcription and activate or repress various biological pathways and effect therapeutic results for various conditions. There are a...
    Published: 8/27/2025
    Inventor(s): Carl Wagner, Peter Jurutka, Pamela Marshall, Arjan Van Der Vaart
    Keywords(s): Bio-Technology, Drug Screening
    Category(s): Life Science (All LS Techs), Cancer Therapeutics, Pharmaceuticals, Neurodegenerative Disease Technologies, Non-Cancer Therapeutics
  4. Modulating the Production of Neuroactive Molecules by Gut Microbes
    Inhibitory neurotransmitters, such as y-aminobutyric acid (GABA), taurine, taurine analogs and β-alanine, have been associated with neurological disorders such as epilepsy, schizophrenia, dementia, autism, Alzheimer’s disease (AD) and more. Additionally, gut microbiome dysbiosis has also been linked to many neurological disorders, with modulations...
    Published: 8/27/2025
    Inventor(s): Dhara Shah, Pavani Dadi
    Keywords(s):  
    Category(s): Proteomic Assays/Reagents/Tools, Pharmaceuticals, Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Microbiome, Life Science (All LS Techs)
  5. Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
    Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
    Published: 8/27/2025
    Inventor(s): Michael Sierks, Stephanie Williams
    Keywords(s): Alzheimer's Disease, Bioassay, biomarker, Neurodegenerative Disorders, Neurological Disorders
    Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Proteomic Assays/Reagents/Tools, Non-Cancer Therapeutics
  6. Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
    Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
    Published: 8/27/2025
    Inventor(s): Michael Sierks, Lalitha Venkataraman, Wei Xin
    Keywords(s): Alzheimer's Disease, CNS Therapeutics, Dementias, Neurodegenerative Disorders, Neurological Disorders, Phage display
    Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools
  7. Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
    Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
    Published: 8/27/2025
    Inventor(s): Michael Sierks, Stephanie Williams, Lalitha Venkataraman
    Keywords(s): AFM, Antibody Therapeutics, Antigen-specific Therapies, Bioassay, Bio-Technology, CNS Therapeutics, Therapeutics
    Category(s): Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools, Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices
  8. Replication System, Novel Polymerases, and Uses for Threose Nucleic Acid
    Synthetic genomics, though a relatively nascent field, is generating a lot of excitement in the scientific community, especially with the advent of unnatural nucleic acid polymers. Threose nucleic acid (TNA) is one such unnatural nucleic acid polymer that is particularly promising because of its high resistance to nuclease degradation, making it much...
    Published: 8/27/2025
    Inventor(s): John Chaput, Matthew Dunn
    Keywords(s): Synthetic Polymerases
    Category(s): Cancer Therapeutics, Diagnostic Assays/Devices, Genomic Assays/Reagents/Tools, Life Science (All LS Techs), Non-Cancer Therapeutics
  9. A novel Scaffold for Mode-Selective Inhibition of TRPV1
    Pain is estimated to affect about 30% of the world’s population and treatment is challenging because of issues with addiction and withdrawal which accompany many current analgesics. Human TRPV1 is a widely expressed nociceptor and is a desirable target to modulate diverse human pathophysiologies, including pain, obesity, and diabetes, among others....
    Published: 4/2/2025
    Inventor(s): Wade Van Horn, Pankaj J. Pasricha
    Keywords(s):  
    Category(s): Life Science (All LS Techs), Non-Cancer Therapeutics, Pharmaceuticals, Advanced Materials/Nanotechnology, Artificial Intelligence/Machine Learning, Biomaterials
  10. Metabolic Reprogramming of Immune for Autoimmune Disorders Prevention/Reversal
    Antigen-specific immune suppression or tolerance is a highly attractive strategy to prevent inflammation-induced tissue damage in rheumatoid arthritis (RA). Although there is insufficient knowledge about autoantigens in human RA, generating and expanding synovium-specific regulatory T cells, and suppressing synovium-specific follicular T-helper cells,...
    Published: 2/19/2025
    Inventor(s): Abhinav Acharya, Joslyn Mangal
    Keywords(s):  
    Category(s): Advanced Materials/Nanotechnology, Biomaterials, Life Science (All LS Techs), Non-Cancer Therapeutics, Nucleic Acid/Peptide/Protein Therapies, Pharmaceuticals

Search Inventions

Looking for a technology or invention to commercialize? Arizona State University has more than 300 technologies available for licensing. Start your search here or submit your own invention.